Jiangsu Recbio Technology Co., Ltd. (2179.HK)
HKD 8.0
(2.56%)
HKD 8.0
(2.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 640.08 Million CNY | -26.85% |
| 2022 | 875.07 Million CNY | 42.69% |
| 2021 | 613.26 Million CNY | 315.83% |
| 2020 | 147.47 Million CNY | 97.16% |
| 2019 | 74.79 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 130.72 Million CNY | 0.0% |
| 2024 Q1 | 130.72 Million CNY | -15.32% |
| 2023 Q4 | 154.36 Million CNY | -5.25% |
| 2023 FY | 626.79 Million CNY | -28.37% |
| 2023 Q2 | 150.47 Million CNY | 0.0% |
| 2023 Q3 | 162.92 Million CNY | 8.28% |
| 2023 Q1 | 150.47 Million CNY | -24.07% |
| 2022 Q2 | 182.7 Million CNY | 0.0% |
| 2022 Q1 | 182.7 Million CNY | 44.16% |
| 2022 FY | 875.07 Million CNY | 42.69% |
| 2022 Q4 | 198.17 Million CNY | 0.0% |
| 2022 Q3 | 198.17 Million CNY | 8.46% |
| 2021 FY | 613.26 Million CNY | 315.83% |
| 2021 Q3 | 201.19 Million CNY | 44.69% |
| 2021 Q2 | 139.04 Million CNY | 0.0% |
| 2021 Q1 | 139.04 Million CNY | 63.89% |
| 2021 Q4 | 126.74 Million CNY | -37.01% |
| 2020 Q4 | 84.84 Million CNY | 0.0% |
| 2020 FY | 147.47 Million CNY | 97.16% |
| 2019 FY | 74.79 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 325.05 Million HKD | -96.919% |
| CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 13.415% |